Service de Médecine Interne-Immunologie clinique, Hôpital Bicêtre, Université Paris Sud, Paris, France.
INSERM CESP Centre for Research in Epidemiology and Population Health, Epidemiology of HIV and STI Group, Paris, France.
Clin Microbiol Infect. 2016 Mar;22(3):268.e1-8. doi: 10.1016/j.cmi.2015.11.018. Epub 2015 Dec 12.
Reactive haemophagocytic syndrome (HS) is a rare condition that occurs in patients with infections, haematological malignancies or autoimmune diseases. Although various microorganisms are thought to trigger HS, most of the literature data on this topic have been gathered in single-centre case series. Here, we sought to characterize infectious triggers in a large, multicentre cohort of patients with HS. Patients were included in the present study if HS was solely due to one or more infections. Detailed microbiological data were recorded. Of the 162 patients with HS in the cohort, 40 (25%) had at least one infection and 38 of the latter (including 14 women, 36.8%) were included. The median age was 46 years. Seven patients were presumed to be immunocompetent (18.4%), whereas 19 patients (50%) were infected with human immunodeficiency virus and 12 patients (31.6%) were immunocompromised for other reasons. Twenty-seven patients (71.1%) had a single infection, whereas six (15.8%) and five (13.1%) patients had, respectively, two and three concomitant infections. We observed pyogenic bacterial infections (n = 7), tuberculosis (n = 10), non-tuberculous mycobacteriosis (n = 3), viral infections (n = 17: 11 cytomegalovirus, three Epstein-Barr virus, two human herpesvirus 8, one herpes simplex virus 2), parasitic infections (n = 8: four disseminated toxoplasmosis, one leishmaniasis, three malaria), fungal infections (n = 5: four pulmonary pneumocystosis and one candidaemia). Eighteen patients (47.4%) received corticosteroids and/or etoposide. Twelve patients died (31.6%). All multiple infections and all deaths occurred in immunocompromised patients. When compared with patients suffering from malignancy-associated HS, patients with infection-triggered HS were younger and more likely to be immunocompromised, and had a better outcome.
反应性噬血细胞综合征(HS)是一种罕见的疾病,发生于感染、血液系统恶性肿瘤或自身免疫性疾病的患者中。尽管各种微生物被认为会引发 HS,但关于这一主题的大多数文献数据都是在单一中心病例系列中收集的。在这里,我们试图在一个由大量多中心 HS 患者组成的队列中描述感染触发因素。如果 HS 仅由一种或多种感染引起,则将患者纳入本研究。记录了详细的微生物学数据。在队列中的 162 名 HS 患者中,有 40 名(25%)至少有一种感染,其中 38 名(包括 14 名女性,36.8%)被纳入。中位年龄为 46 岁。7 名患者被认为免疫功能正常(18.4%),19 名(50%)感染人类免疫缺陷病毒,12 名(31.6%)因其他原因免疫功能低下。27 名(71.1%)患者有单一感染,6 名(15.8%)和 5 名(13.1%)患者分别有 2 种和 3 种合并感染。我们观察到化脓性细菌感染(n=7)、结核病(n=10)、非结核分枝杆菌病(n=3)、病毒感染(n=17:11 例巨细胞病毒、3 例 EBV、2 例人类疱疹病毒 8、1 例单纯疱疹病毒 2)、寄生虫感染(n=8:4 例播散性弓形虫病、1 例利什曼病、3 例疟疾)、真菌感染(n=5:4 例肺孢子菌病和 1 例念珠菌血症)。18 名患者(47.4%)接受了皮质类固醇和/或依托泊苷治疗。12 名患者死亡(31.6%)。所有合并感染和所有死亡均发生在免疫功能低下的患者中。与恶性肿瘤相关性 HS 患者相比,感染性 HS 患者更年轻、更可能免疫功能低下,且预后更好。